Preparing for a GMP inspection from 2026. GAP analysis, CAPA, staff training and the consequences of critical deficiencies


The validity of a license to manufacture medicines for medical use and (or) of a certificate of compliance with the good manufacturing practice rules of the Eurasian Economic Union (Union GMP) is suspended for no more than 120 days from the date of the licensing authority’s decision if an assessment of compliance with licensing requirements identifies gross violations that are classified as critical Union GMP deficiencies and have resulted in the consequences established by Federal Law No. 99-FZ of 4 May 2011 «On the Licensing of Certain Types of Activities» (hereinafter 99-FZ). This is provided for in Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (hereinafter 61-FZ). The provision was introduced by Federal Law No. 324-FZ of 4 August 2026 «On Amendments to the Federal Law ‘On the Circulation of Medicines’ and Certain Legislative Acts of the Russian Federation» (hereinafter 324-FZ). It has been in force since 15 August 2026.
Critical and major deficiencies are recorded in the inspection report under the Rules for Conducting Pharmaceutical Inspections for Compliance with the Requirements of the Union’s Good Manufacturing Practice Rules, approved by Decision of the Council of the Eurasian Economic Commission (EEC) No. 83 of 3 November 2016 (hereinafter the Inspection Rules). A critical deficiency causes or leads to a significant risk of producing a medicine that is dangerous to human health and life. The response to critical and major deficiencies includes a corrective and preventive action (CAPA) plan, a report on its implementation and evidence of remediation. It is submitted within 60 calendar days from receipt of Part I of the report. If the response is not submitted on time, the manufacturing operations are deemed non-compliant with Union GMP.

What changed on 1 March 2026

Since 1 March 2026, medicines for medical use in Russia are manufactured under the Union GMP rules, and manufacturing that does not follow those rules is prohibited. These provisions were introduced into 61-FZ by Federal Law No. 304-FZ of 31 July 2025 «On Amendments to Certain Legislative Acts of the Russian Federation» (hereinafter 304-FZ). The Union GMP rules are approved by Decision of the EEC Council No. 77 of 3 November 2016 «On Approval of the Good Manufacturing Practice Rules of the Eurasian Economic Union» (hereinafter the GMP Rules).

Table 1. Confirmation of a Russian manufacturer’s GMP compliance before and after 1 March 2026

IssueBefore 1 March 2026As of 17 October 2026
GMP rules applied by the manufacturerRules approved by the authorized federal body. These are Order of the Russian Ministry of Industry and Trade No. 916 of 14 June 2013 «On Approval of the Good Manufacturing Practice Rules» (hereinafter Order No. 916)The GMP Rules. Order No. 916 was recognized as repealed by Order of the Russian Ministry of Industry and Trade No. 3093 of 25 June 2026. It ceased to have effect on 9 August 2026
Inspection procedureThe Rules for Organizing and Conducting Inspections of Manufacturers of Medicines for Compliance with the Requirements of Good Manufacturing Practice Rules, approved by Resolution of the Government of the Russian Federation No. 1314 of 3 December 2015 (hereinafter Resolution No. 1314). The Russian Ministry of Industry and Trade inspected a Russian manufacturer as part of licensing controlResolution No. 1314 ceased to have effect on 1 March 2026 under Resolution of the Government of the Russian Federation No. 1766 of 8 November 2025 «On Recognizing Certain Acts of the Government of the Russian Federation as Repealed». The procedure is set by the Inspection Rules
Compliance documentA conclusion on the manufacturer’s compliance, valid for 3 years from completion of the inspectionA certificate of compliance issued as a result of licensing, valid for no more than 3 years from completion of the inspection (under the Regulation on the Licensing of the Manufacture of Medicines, approved by Resolution of the Government of the Russian Federation No. 686 of 6 July 2012, hereinafter the Licensing Regulation, and under the Inspection Rules)
Manufacturer’s deadline for responding to deficienciesThe Rules under Resolution No. 1314 set no deadline for a Russian manufacturer: a CAPA plan and a deadline of 60 working days were named only for a foreign manufacturerNo later than 60 calendar days from receipt of Part I of the report if critical and (or) major deficiencies have been identified
Classification of deficienciesThe Rules under Resolution No. 1314 did not distinguish critical, major and other deficienciesCritical, major and other deficiencies; the definitions are given in the report template under the Inspection Rules
Inspection time limitUp to 160 working days from the decision to conduct the inspection; the inspection itself lasted no more than 10 working days, excluding travel timeThe Inspection Rules do not name a maximum duration
Consequence of non-complianceA ground for refusing to issue a conclusion: the manufacturer’s non-compliance with GMP requirementsThe manufacturing operations are deemed non-compliant; suspension or termination of the license and (or) certificate

Conclusions on a manufacturer’s compliance issued as documents before 1 March 2026 remain valid until their validity period ends (this is provided for by 304-FZ). As of 17 October 2026, 304-FZ, Resolution No. 1766 and the Inspection Rules contain no provisions on inspections begun before 1 March 2026. 324-FZ likewise contains no transitional provisions.
The Russian Ministry of Industry and Trade organizes and conducts pharmaceutical inspections of the manufacture of medicines for medical use and issues certificates. This is set out in the Regulation on the Ministry of Industry and Trade of the Russian Federation, approved by Resolution of the Government of the Russian Federation No. 438 of 5 June 2008 (as amended on 11 June 2026).

The inspection procedure

Inspections are either scheduled or unscheduled. They are conducted by decision of the authorized body of a Union member state and (or) on the application of the entity subject to inspection, for example for licensing, registration or an investigation related to the quality of medicinal products. The inspection is conducted by the pharmaceutical inspectorate of the member state in whose territory the site is located. The General Requirements for the Quality System of Pharmaceutical Inspectorates, approved by Decision of the EEC Council No. 82 of 3 November 2016, define a pharmaceutical inspectorate as a structural unit of the authorized body or authorized organization of a member state in the sphere of the circulation of medicines that conducts pharmaceutical inspections. Remote inspection is permitted by decision of the inspectorate in an emergency and (or) where there is a threat of epidemic diseases and of injuries caused by adverse chemical, biological or radiation factors, and also in force majeure circumstances that threaten the life and health of inspectors.
To arrange an inspection, a Russian manufacturer ensures submission of an application, a copy of the manufacturing site dossier (the site master file) prepared under the GMP Rules, with a copy of the license (where available), and a list of the medicines it manufactures in the form given in the Inspection Rules. An inspection may be refused in the following cases: information in the application or in documents submitted on request is incomplete and (or) inaccurate; the applicant has not provided the conditions for the inspection, which makes it impossible to conduct; inspection expenses have not been paid within the established period, where this applies. Inspection expenses are borne by the entity subject to inspection or its authorized representative.
The inspection team consists of at least two people. Before the inspection, the team reviews the site master file and other information, for example on complaints, quality defects and product recalls obtained from state registers and databases. The manufacturer designates a person responsible for assisting with the inspection. The contract with the inspectorate must reflect, among other things, the following rights of the inspector: access to any premises under the program, obtaining documentation, photo and video materials, questioning responsible persons and observing work at workplaces. At the end of each day, the team discusses its preliminary observations, and deficiencies that it plans to classify as critical are reported to the responsible persons immediately. A deficiency remedied during the inspection remains in the report, with a note that it has been remedied.

Table 2. Time limits under the Inspection Rules

StageTime limit
Sending the inspection program to the manufacturerNo later than 10 working days before the start date
Informing the head of the inspectorate and the head of the manufacturer of a risk to the life and health of the population, including potential critical deficienciesWithin 24 hours of identification
Signing Part I of the report where critical and (or) major deficiencies have been identifiedNo later than 30 calendar days from completion of the inspection or, where samples are taken, from receipt of their test results
Sending a copy of the report to the manufacturerNo later than 3 working days from the date of signing
Manufacturer’s response: CAPA plan, implementation report, evidence of remediationNo later than 60 calendar days from receipt of Part I
Signing Part II of the reportNo later than 30 calendar days from submission of the response; if the response is not submitted on time, on the 61st calendar day from receipt of Part I
Notifying the manufacturer of the suspension or termination of a previously issued certificate where critical deficiencies have been identifiedNo later than 5 working days from completion of the inspection
Issuing the certificateNo later than 10 working days from the decision to issue it
Certificate validityNo more than 3 years from completion of the inspection

A critical deficiency causes or leads to a significant risk of producing a medicine that is dangerous to human health and life. A major deficiency cannot be classified as critical, but it has led or may lead to the production of a medicine that does not comply with the registration dossier, indicates a major deviation from the GMP Rules or from the requirements of other acts in the sphere of the circulation of medicines, or indicates that the entity subject to inspection is unable to manufacture batches of medicinal products of consistent quality or that its authorized person is unable to perform their duties. A combination of deficiencies, none of which is major on its own but which together constitute a major deficiency, is also classified as major: the inspectors explain that assessment and record it as a major deficiency. A deficiency classified as other is neither critical nor major and indicates a deviation from the GMP Rules. The definitions are given in the report template under the Inspection Rules.
For other deficiencies, the team assesses the CAPA plan and its implementation report at the next inspection.

Consequences of critical and major deficiencies

Manufacturing operations are deemed compliant with Union GMP if there are no deficiencies, no critical or major deficiencies, or all of them have been remedied as established by the assessment of the response. They are deemed non-compliant in any of the following cases: the report identifies critical and (or) major deficiencies; they have not been remedied as established by the assessment of the response; the response has not been submitted on time; the inspector was obstructed in exercising the rights reflected in the contract with the inspectorate. A certificate is refused if the manufacturing operations are deemed non-compliant.
If critical deficiencies are identified, the inspectorate sends written notification to the authorized body, which may suspend or terminate the validity of a previously issued certificate and notifies the manufacturer in writing no later than 5 working days from completion of the inspection. The decision to resume the validity of a suspended certificate is taken after review of the CAPA plan, the report on its implementation and the evidence that the deficiencies have been remedied.
The Licensing Regulation includes compliance with the GMP Rules among the licensing requirements. Failure to meet this requirement that has resulted in the consequences established by 99-FZ is recognized as a gross violation. Such consequences include, for example, a threat of harm to the life and health of citizens. Union GMP compliance is confirmed during licensing, and a certificate is issued if the result is positive. Following the compliance assessment and periodic confirmation of compliance of a licensee that manufactures medicines for medical use, a document is drawn up in the form of the report under the Inspection Rules.
Under 61-FZ, the consequences depend on the type of deficiency:
Critical deficiencies constituting gross violations: the validity of the license and (or) certificate is suspended in respect of all or some of the work covered by the license and (or) certificate for no more than 120 days from the date of the licensing authority’s decision. If the licensee operates at several locations, the license may be suspended for one or more locations. The suspension period can be extended by 60 days on the licensee’s application, which is submitted no earlier than 60 days after the licensing authority’s decision to suspend.
Major deficiencies constituting gross violations: the provisions of 99-FZ to which 61-FZ refers apply.
Resumption and termination: the validity of a suspended license and (or) certificate is resumed by decision of the licensing authority under the procedure established by 99-FZ. If the licensee has not remedied the violations during the suspension period, the licensing authority terminates the validity of the license and (or) certificate when the suspension period expires
.

GAP analysis before the inspection

GAP analysis compares the requirements of the GMP Rules with what happens at the site; the difference between them is the gap. Neither the GMP Rules nor the Inspection Rules provide for GAP analysis as a procedure. For its own review, a company takes the documents the inspectorate works from: the inspection program, the checklists and the classification of deficiencies in the report template. All of them are given in the Inspection Rules. The program lists the inspection areas by section of the GMP Rules and their annexes, including the corrective and preventive action system, the training system and self-inspection.
The site master file is kept up to date so that it reflects current operations. It includes a description of computerized systems relevant to compliance with the requirements of the GMP Rules and a brief description of the self-inspection system, with the criteria for selecting the areas to be inspected.
On data integrity, the GMP Rules require records to be made as each action is performed. Any amendment to a document is signed and dated so that the original information remains legible, and the reason for the amendment is stated where applicable. There must be reliable controls that ensure the integrity of the record throughout its retention period. Batch documentation is retained for 1 year after the batch expiry date or for at least 5 years after the Qualified Person (QP) has authorized the batch for release, whichever is longer. The GMP Rules have a separate annex on computerized systems. Recommendation of the EEC Board No. 25 of 19 September 2023 «On the Guideline on Ensuring Data Integrity and the Validation of Computerized Systems» (hereinafter Recommendation No. 25) annexes a Guideline that defines data integrity as the degree to which data are complete, consistent and accurate throughout their life cycle, and extends its principles to electronic and paper-based systems. Recommendation No. 25 has no binding force: member states are recommended to take the Guideline into account.
Measures against cross-contamination must be proportionate to the risks, and quality risk management principles are used to assess and manage the risks.
The product quality review includes the qualification status of equipment and utilities, for example heating, ventilation and air conditioning systems, water systems and compressed gas systems. The same review includes starting materials, with particular attention to materials from new suppliers, and a separate review of the traceability of the active pharmaceutical ingredient supply chain.
Decision of the EEC Council No. 103 of 9 September 2026 «On Amendments to the Good Manufacturing Practice Rules of the Eurasian Economic Union» (hereinafter Decision No. 103) enters into force after 30 calendar days from the date of its official publication, that is, on 28 October 2026. In the GMP Rules, it replaces the wording on deviations from specifications and non-compliance with them with wording on out-of-specification results. In two annexes to the GMP Rules, it replaces the words «boundaries» and «bounds» with «limits». It excludes advanced therapy medicinal products from the scope of two annexes to the GMP Rules and adds a new section on the manufacture of such products. Decision No. 103 does not change the requirements of the GMP Rules on which this article relies.
Decision of the EEC Council No. 67 of 20 May 2026 «On Amendments to the Good Manufacturing Practice Rules of the Eurasian Economic Union» (hereinafter Decision No. 67) replaces the annex to the GMP Rules on sterile medicines with a revised version. It enters into force after 180 calendar days from the date of its official publication, that is, on 28 December 2026. Some provisions of the new annex enter into force later, after 1,095 calendar days from the date of official publication.

CAPA that inspectors will review

The GMP Rules include CAPA in the pharmaceutical quality system. When deviations, suspected product defects and other problems are investigated, the level of root cause analysis applied can be determined using quality risk management principles. If the true cause cannot be established, the most probable one is identified. Human error is established as a cause with particular care, so that process, procedural or system problems are not overlooked. Following the investigation, corrective and preventive actions are identified and taken, and their effectiveness is checked and assessed using quality risk management principles. The GMP Rules apply the same requirements to quality defects, and defect records are reviewed regularly, with trend analysis to identify recurring problems.
The product quality review is conducted, as a rule, annually. It includes a review of significant deviations and non-conformances, the investigations related to them, the effectiveness of the corrective and preventive actions taken, and the adequacy of earlier corrective actions relating to manufacturing or equipment. The results of the review are used to decide whether corrective and preventive actions are needed, and the effectiveness of the procedures for managing such actions is confirmed during self-inspection.
Under the GMP Rules, self-inspection covers personnel, premises, equipment, documentation, the manufacturing process, quality control, distribution, the handling of complaints and recalls, and the self-inspection activities themselves. It is conducted independently and thoroughly by a specially designated qualified member of the company’s staff, and external experts are involved where necessary. The report contains all observations and proposals for corrective actions; the actions taken as a result are also documented.
The GMP Rules do not name a root cause analysis method or a period for monitoring the effectiveness of actions, and they do not define which CAPA is considered closed.

Staff who will answer inspectors’ questions

An inspector is entitled to question responsible persons and to observe work at workplaces. Staff training is regulated by the GMP Rules:
everyone whose duties involve being in production or storage areas or control laboratories undergoes training, including technical and maintenance staff and cleaning staff, as well as other personnel whose activities may affect quality;
every newly hired employee undergoes basic training and initial training in their job duties, then continuing training with periodic assessment of its effectiveness in practice; the head of production or quality control approves the programs, and training records are retained;
personnel in areas where contamination is a hazard undergo specific training;
visitors and untrained staff are not admitted to production and quality control areas; if admission is unavoidable, they are briefed in advance, accompanied and supervised;
the principles of the pharmaceutical quality system are explained in detail during training;
consultants are recorded separately, with their personal details, residential address, qualifications and the type of services provided.

The acts do not establish a list of inspector’s questions; the topics in Table 3 are derived from the provisions of the GMP Rules.

Table 3. GMP Rules provisions from which questions to an employee follow

Question topicWhat the GMP Rules require
How a record is correctedThe amendment is signed and dated, the original information remains legible, and the reason for the amendment is stated where applicable
Which document the employee works fromQuality management system documents are reviewed regularly, and use of obsolete versions is excluded
When a record is madeRecords are made as each action is performed
Admission of visitors and untrained staffThey are not admitted to production and quality control areas without briefing and accompaniment
Conduct in production and storage areasSmoking, eating, drinking, chewing and storing food, drinks, tobacco products and personal medicinal products are prohibited
Where training is confirmed by recordsTraining records are retained

What to do

Define the scope of the analysis. Check dosage forms and manufacturing operations against the license, the site master file and the certificate: the certificate covers the dosage forms and manufacturing operations specified in it, and a copy of the site master file is attached to the application for the inspection. Check that the site master file reflects the current activities of the site.
Conduct a GAP analysis using the inspection program and the checklist. Take the inspection areas of the program and the checklist template from the Inspection Rules. Assign each gap a category under the definitions in the report template: critical, major or other deficiency. Document the results of the GAP analysis in a register of gaps with the people responsible. Take account of the amendments to the GMP Rules under Decision No. 103 and Decision No. 67 from their effective dates.
Close the gaps through CAPA. For each gap, record the root cause, the action, the person responsible, the deadline and the effectiveness criterion. Close the CAPA after verifying effectiveness against that criterion. Include the results in the annual product quality review.
Check records and training. Check paper and electronic records against the documentation requirements of the GMP Rules and their annex on computerized systems, and data handling procedures against Recommendation No. 25. Check training programs and records, the assessment of training effectiveness in practice, and the procedure for admitting visitors. Designate a person responsible for assisting with the inspection.
Conduct a self-inspection and prepare a response timetable. Self-inspection is conducted under a program and schedule, independently, with the report and the actions taken documented; involve external experts where necessary. Define in advance who is responsible and the deadlines in case the report contains critical or major deficiencies: 24 hours to report a risk, 60 calendar days from receipt of Part I to submit a response, and 5 working days for notification of the suspension of a certificate.


Regulatory framework:

1. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended on 4 August 2026, applicable from 1 September 2026)
2. Federal Law No. 304-FZ of 31 July 2025 «On Amendments to Certain Legislative Acts of the Russian Federation» (as amended on 4 August 2026)
3. Federal Law No. 324-FZ of 4 August 2026 «On Amendments to the Federal Law ‘On the Circulation of Medicines’ and Certain Legislative Acts of the Russian Federation»
4. Federal Law No. 99-FZ of 4 May 2011 «On the Licensing of Certain Types of Activities» (as amended on 4 August 2026)
5. Resolution of the Government of the Russian Federation No. 686 of 6 July 2012 «On Approval of the Regulation on the Licensing of the Manufacture of Medicines» (as amended on 25 December 2025)
6. Resolution of the Government of the Russian Federation No. 1314 of 3 December 2015 «On Determining the Compliance of Manufacturers of Medicines with the Requirements of Good Manufacturing Practice Rules» (as amended on 5 September 2020, ceased to have effect on 1 March 2026)
7. Resolution of the Government of the Russian Federation No. 1766 of 8 November 2025 «On Recognizing Certain Acts of the Government of the Russian Federation as Repealed»
8. Resolution of the Government of the Russian Federation No. 438 of 5 June 2008 «On the Ministry of Industry and Trade of the Russian Federation» (as amended on 11 June 2026)
9. Order of the Russian Ministry of Industry and Trade No. 916 of 14 June 2013 «On Approval of the Good Manufacturing Practice Rules» (repealed)
10. Order of the Russian Ministry of Industry and Trade No. 3093 of 25 June 2026 «On Recognizing as Repealed the Order of the Ministry of Industry and Trade of the Russian Federation No. 916 of 14 June 2013 ‘On Approval of the Good Manufacturing Practice Rules’ and the Amendments Made to It»
11. Decision of the Council of the Eurasian Economic Commission No. 83 of 3 November 2016 «On Approval of the Rules for Conducting Pharmaceutical Inspections» (as amended on 1 August 2025)
12. Decision of the Council of the Eurasian Economic Commission No. 82 of 3 November 2016 «On Approval of the General Requirements for the Quality System of Pharmaceutical Inspectorates of the Member States of the Eurasian Economic Union»
13. Decision of the Council of the Eurasian Economic Commission No. 77 of 3 November 2016 «On Approval of the Good Manufacturing Practice Rules of the Eurasian Economic Union» (as amended on 4 July 2023)
14. Decision of the Council of the Eurasian Economic Commission No. 103 of 9 September 2026 «On Amendments to the Good Manufacturing Practice Rules of the Eurasian Economic Union»
15. Decision of the Council of the Eurasian Economic Commission No. 67 of 20 May 2026 «On Amendments to the Good Manufacturing Practice Rules of the Eurasian Economic Union»
16. Recommendation of the Board of the Eurasian Economic Commission No. 25 of 19 September 2023 «On the Guideline on Ensuring Data Integrity and the Validation of Computerized Systems»

This page in Russian→